Galmed
GLMD
Galmed (GLMD) news
Recent news
Madrigal Pharmaceuticals reports three new resmetirom patents
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has recently received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent covering the FDA-approved use of Rezdiffra™ (resmetirom), the company’s treatment for noncirrhotic metabolic dysfunction-associated…
AInvest Wire · Jul 13, 2026Galmed Pharmaceuticals - increases cash payment by $800k, restructures $2 mln earnout starting Q3 2027
AInvest Wire · Jun 22, 2026Galmed Pharmaceuticals - Colospan shareholders to receive $2.5 mln cash and $2 mln in Galmed shares at closing
AInvest Wire · Jun 8, 2026Galmed Pharmaceuticals - plans $6 mln investment to launch Colospan device in Europe during H2 2026
AInvest Wire · Jun 8, 2026Galmed Pharmaceuticals to acquire Colospan to create a GI-focused platform targeting a $6 billion market
AInvest Wire · Jun 8, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.